MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$9,839K
Net Income
-$38,533K
Net Profit Margin
-391.64%
EPS
-$2.33
Unit: Thousand (K) dollars
Revenue Breakdown
Astellas Pharma Inc Astellas
Vaxcyte Inc
Other
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
9,839
14,523
11,647
9,693
Research and development
31,695
36,553
25,858*
39,853
General and administrative
7,831
7,584
12,393*
8,741
Restructuring and related costs
201
42
11,445*
9,558
Total operating expenses
39,727
44,179
49,696
58,152
Loss from operations
-29,888
-29,656
-38,049
-48,459
Interest income
1,723
1,635
1,534
2,009
Non-cash interest expense related to the sale of future royalties
9,862
9,467
9,547
9,670
Interest and other income (expense), net
-505
-1,011
-775
-737
Loss before provision for income taxes
-38,532
-38,499
-46,828*
-56,857
Provision for / (benefit) from income taxes
1
-15
-66*
0
Net loss
-38,533
-38,484
-46,762
-56,857
Basic EPS
-2.33
-2.94
0.214
-0.67
Diluted EPS
-2.33
-2.94
0.214
-0.67
Basic Average Shares
16,571,602
13,082,355
-218,564,810
84,869,864
Diluted Average Shares
16,571,602
13,082,355
-218,564,810
84,869,864
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$38,533K
(-235.10%↓ Y/Y)
Loss before
provision for income taxes
-$38,532K
(-234.57%↓ Y/Y)
Provision for / (benefit)
from income taxes
$1K
(105.56%↑ Y/Y)
Interest income
$1,723K
(-31.60%↓ Y/Y)
Astellas Pharma Inc
Astellas
$9,637K
Vaxcyte Inc
$177K
Other
$25K
Loss from operations
-$29,888K
(-793.51%↓ Y/Y)
Non-cash interest
expense related to the...
$9,862K
(2.23%↑ Y/Y)
Revenue
$9,839K
(-84.57%↓ Y/Y)
Interest and other income
(expense), net
-$505K
(51.63%↑ Y/Y)
Total operating
expenses
$39,727K
(-40.79%↓ Y/Y)
Research and development
$31,695K
(-17.30%↓ Y/Y)
General and
administrative
$7,831K
(-24.29%↓ Y/Y)
Restructuring and related
costs
$201K
(-98.91%↓ Y/Y)
Buy us a coffee
SUTRO BIOPHARMA, INC. (STRO)
SUTRO BIOPHARMA, INC. (STRO)